Sign In
Buy NBIX
$164.18
-1.88 (-1.13%)
At Close: Jun 25, 2026
Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes"
01:45pm, Wednesday, 24'th Jun 2026
Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.
Best Momentum Stocks to Buy for June 24th
11:01am, Wednesday, 24'th Jun 2026
NBIX, ILPT and CASY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 24th, 2026.
New Strong Buy Stocks for June 24th
05:06am, Wednesday, 24'th Jun 2026
BY, NVGS, NBIX, TFII and BG have been added to the Zacks Rank #1 (Strong Buy) List on June 24th, 2026.
Best Value Stocks to Buy for June 24th
04:36am, Wednesday, 24'th Jun 2026
NVGS, BY and NBIX made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 24th, 2026.
Participants who resumed VYKAT XR following a 16-week randomized withdrawal period demonstrated improvements in hyperphagia and behavioral symptoms as early as Week 13, with benefits continuing throug
Androstenedione and other adrenal hormone levels in 11β‑hydroxylase-deficient patients improved substantially after initiation of CRENESSITY, with >90% median reductions in 11-deoxycortisol and 11-
Two-year data showed that pediatric patients with accelerated bone age at baseline experienced slowed bone age progression and improved predicted adult height with CRENESSITY Cross-sectional caregiver
Two-year CRENESSITY data in adults showed improvements in cardiometabolic outcomes of insulin resistance, body composition and body weight alongside sustained reductions in glucocorticoid dose Among p
Neurocrine Biosciences, Inc. (NBIX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
03:52pm, Tuesday, 09'th Jun 2026
Neurocrine Biosciences, Inc. (NBIX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
New 48-week KINECT® 4 post-hoc analysis shows 94% of participants treated with INGREZZA achieved either symptomatic remission or a clinically meaningful response (≥30% reduction from baseline in Ab
Nearly all individuals with intellectual and developmental disabilities experienced improvement in tardive dyskinesia severity after starting INGREZZA, and of those, 89% experienced improvement within
Neurocrine Biosciences to Present New TwoâYear CRENESSITYÂ (crinecerfont) Data on Key Clinical and PatientâReported Outcome Measures at EN
Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and reflect longer-term clinical outcomes relevant to disease management across lifespan and care contin
Neurocrine Biosciences, Inc. (NBIX) Presents at 46th Annual William Blair Growth Stock Conference Transcript
01:51pm, Tuesday, 02'nd Jun 2026
Neurocrine Biosciences, Inc. (NBIX) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
04:01pm, Tuesday, 26'th May 2026
SAN DIEGO, May 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: William Blair 46 th Annu
